Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ABT-122 plus methotrexate in active rheumatoid arthritis with inadequate response to methotrexate
2013-004019-37Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2014
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of remtolumab in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: ACR20 response rate at Week 12. Started Jul 2014; status: completed.
02
Drugs
remtolumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-004019-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004019-37.